P ulmonary vein (PV) isolation is an effective therapy to alleviate symptoms and restore sinus rhythm in patients with atrial fibrillation (AF). 1 However, recent reports have shown that ablation in the left atrium (LA) is associated with new asymptomatic cerebral emboli (ACE) visible on postprocedural diffusion-weighted cerebral MRI. 2 The largest such study reported an ACE incidence of 14.2% using openirrigation radiofrequency (RF) catheters. 3 Although no patient parameters were correlated with ACE, procedural parameters, such as cardioversion and activated clotting time (ACT) level, were associated with new silent lesions. Smaller subsequent reports with rates ranging from 7% to 12% have similarly implicated procedural factors to increasing ACE incidence, including concomitant diagnostic coronary angiography, 4 total RF duration, 5 and non-PV ablation. 6
October 2013
particles were observed when activated electrodes were provocatively overlapped during ablation. These gaseous and solid emboli were found to be the cause of cerebral embolic MRI findings in animal models similar to those seen in humans. 10 Thus, the aim of this study was to establish if ACE incidence in patients could be reduced by applying specific procedural techniques identified in the preclinical setting to reduce the embolic load.
Methods

Patient Population
The study population consisted of 68 subjects enrolled at 1 Canadian and 6 European centers, all experienced with the circular MER ablation system. To be eligible for the study, patients had to be >18 years of age and had symptomatic AF indicated for catheter ablation. Exclusion criteria included prior AF ablation, recent history of cerebral vascular accident (<6 months), contraindication to MRI, contraindication to vitamin K antagonism (VKA), active LA thrombus, ablation with nonstudy devices, and pregnancy. The study was approved by each center's ethics review board and all patients gave written informed consent before study inclusion. The study was registered on ClinicalTrials. gov; NCT01520532. Eight subjects were excluded from analysis after enrollment. Seven of the 8 exclusions did not undergo a study ablation procedure because of very subtherapeutic international normalized ratio (INR) on the day of procedure (n=3), use of a different ablation technology (n=1), prior LA ablation (n=1), inability to cross the septum (n=1), and withdrawal of study consent (n=1). One of the 8 exclusions underwent ablation but did not undergo a postprocedure MRI.
Study Design
The Evaluation of Reduction of Asymptomatic Cerebral Embolism (ERACE) trial was a prospective, multicenter, cohort study intended to assess the acute clinical impact of applying specific procedural changes, as compared with previous studies using MER technology, including: (1) performing the procedure on therapeutic, uninterrupted oral VKA with INR >2.0 and intraprocedural heparin to keep ACT >350 seconds;
(2) loading the catheter into the introducer submerged in saline before sheath insertion to reduce air ingress; and (3) deactivation of either the distal or proximal electrode on the MER catheter to avoid electrode overlap and phased RF interaction. These changes were derived from preclinical investigations into embolic load creation. 9 Protocol-defined subject evaluations were conducted preprocedure, immediately postprocedure, and 1 month postprocedure. All visits included a medical history, physical examination with neurological assessment, and protocol-specified cerebral MRI evaluations as detailed below.
Periprocedural Anticoagulation
Administration of oral anticoagulation with VKA to achieve an INR ≥2.0 was initiated ≥4 weeks before the ablation procedure. Oral anticoagulation was maintained throughout the ablation procedure without interruption or bridging and for the duration of follow-up. Patients were targeted to have an INR ≥2.0 on the day of ablation. Novel oral anticoagulants were excluded from this study, including dabigatran, rivaroxaban, and apixaban. Within ). Intravenous unfractionated heparin was administered just before or immediately after transseptal puncture and maintained throughout the ablation procedure to keep the ACT ≥350 seconds. The first RF application was not permitted by protocol until a documented ACT ≥350 seconds was achieved. If the ACT fell <350 seconds during the case, investigators were asked to give an additional bolus of heparin and repeat the ACT immediately afterward. Otherwise, ACTs were monitored every 15 minutes.
Ablation Protocol and Procedural Techniques
The ablation system consisting of a multichannel RF generator and a circular MER ablation catheter (GENius Generator and Pulmonary Vein Ablation Catheter; Medtronic Ablation Frontiers, Carlsbad, CA) has been previously described. 11, 12 Briefly, the circular MER catheter delivers duty-cycled, phased RF energy via the generator to the PV antrum. Phase-shifted energy delivery between adjacent catheter electrodes (bipolar) and return electrodes (unipolar) allows creation of long, contiguous lesions with each RF application. 13 Increasing the ratio of unipolar-to-bipolar energy allows an increase in lesion depth. RF is delivered in temperature-controlled and powerlimited fashion (60°C; 10 W) with typical duration of 60 seconds. Energized electrodes with low power (<3 W) or low temperature (<50°C) were deselected during ablation to minimize ineffective RF delivery. All PVs were isolated using the circular MER catheter by multiple applications of phased RF delivery around each of the PV antra identified by contrast fluoroscopy, intracardiac echography, or preprocedural imaging. Two centers used intracardiac echocardiography routinely (10 French Acuson; Siemens, Erlangen, Germany) and the catheter was kept in the right atrium and was not introduced into the LA. The procedural end point of PV isolation entrance block was assessed via signal interpretation using the circular MER catheter and pacing maneuvers from the PV, coronary sinus, or LA where appropriate. Adenosine or isoproterenol provocation was not systematically performed. To allow for verification of PV isolation, sinus rhythm was restored by direct current cardioversion at the end of procedure, when needed.
To reduce air entrapment around the array, and inadvertent introduction of air into the transseptal sheath and LA, the distal end of the circular MER catheter was submerged and captured by the introduction device in a saline bath immediately before sheath insertion ( Figure 1 ). Transseptal sheaths were also aspirated and flushed with heparinized saline before and after catheter introduction to avoid air ingress. The sheaths were also either periodically or continuously flushed during the ablation procedure with heparinized saline to prevent embolus formation as per each center's practice. Investigators were also asked to avoid any catheter exchanges through the transseptal sheath; both ablation and pacing maneuvers were performed with the same MER catheter without exchanging for other diagnostic/ pacing catheters in the LA.
Finally, to eliminate the possibility of distal and proximal electrode overlap with resulting bipolar electrode electrical interaction ( Figure 2 ), either the distal or proximal electrode was always deactivated before RF delivery.
Cerebral MRI and Neurological Assessments
Cerebral MRI was performed using a 1.5-T scanner (Signa HDxt; GE Healthcare, Milwaukee, WI; Intera/Achieva; Philips, Eindhoven, the Netherlands; or Avanto/Symphony; Siemens) using the same standardized acquisition protocol, which has been described previously 3 Figure 1 . Submerged technique of capturing the catheter inside the sheath introducer. The sheath introducer (arrow) helps to allow introduction of the ablation catheter into the transseptal sheath. To prevent entrapment of air inside this introducer, the introducer and catheter are submerged in sterile saline (left). The catheter is then pulled back into the introducer while submerged in saline so that no air gets into the introducer (middle and right). This minimizes the possibility of any air ingress while the introducer-catheter apparatus is placed into the transseptal sheath for catheter introduction into the left atrium.
(see online-only Data Supplement; eMethods 1). Cerebral MRI scans were performed <7 days preablation and 24 to 48 hours postablation in all subjects. For patients with a new postprocedure finding, the cerebral MRI was repeated at the 1-month visit. The ACE definition used in this trial was identical to that previously described by Gaita et al. 3 Briefly, postprocedural ACE lesions were defined by any new focal hyperintensities detected on the postablation T2-fluid-attenuated inversion recovery images corresponding to restricted diffusion on the diffusion-weighted sequences. Pre-existing lesions (PELs) on cerebral MRI were defined as focal hyperintense areas detected by the T2-fluid-attenuated inversion recovery sequence on the preablation MRI. The number and size of both pre-existing and new cerebral lesions were recorded. All acquired MRIs were sent to a core laboratory and were interpreted by 2 independent, blinded neuroradiologist reviewers. In cases of disagreement, reviewers reached a consensus before final adjudication.
All subjects underwent neurological assessment at each study visit with the Mini-Mental State Exam (MMSE) and the National Institutes of Health (NIH) Stroke Scale. Details of these scales are provided in the online-only Data Supplement (eMethods 2).
Study End Points
The primary end point was incidence of new ACE lesions on postprocedure cerebral MRI. Secondary endpoints included assessment of preablation lesions on MRI; all serious adverse events that were related, or probably related, to the procedure or ablation system; the ability to achieve the end point of PV isolation with the study system; and any new abnormal findings on neurological assessment.
Statistical Analysis
Demographics, medical history, and other clinically relevant variables are summarized using descriptive statistics, including mean±SD, median, range for continuous variables, and percentages for qualitative variables. Comparisons were performed using Pearson χ 2 test for categorical variables and the Student t test or Mann-Whitney U test for parametric or nonparametric continuous variables, respectively. Binomial confidence intervals (95%) were calculated using the Clopper-Pearson method. Repeated measures analysis of variance models were used to compare changes in neurological scores from baseline for all patients and among patients with and without PEL across study visits. Relationship between pre-existing MRI lesions and CHA 2 DS 2 -VASc score was performed by linear regression. A P value of <0.05 was considered statistically significant. Statistical analyses were conducted with IBM SPSS Statistics 20 (IBM, Armonk, NY).
Results
Patient Characteristics
From March to October 2012, 60 subjects completed all scheduled study visits and assessments, with baseline characteristics detailed in Table 1 . The study population had a mean age of 60±10 years and modest left atrial enlargement (42±5 mm).
Figure 2.
Fluoroscopic views of the circular multielectrode radiofrequency ablation catheter. These images demonstrate how the most distal and most proximal electrodes on the ablation catheter can overlap with one another if the catheter is manipulated accordingly (arrows). Because these 2 electrodes are out of phase during phased radiofrequency delivery, a short circuit between the 2 electrodes can occur. Such a short circuit has been shown to create large volumes of both gaseous and solid embolic materials, which can contribute to occurrence of asymptomatic cerebral emboli. LAO indicates left anterior oblique; and RAO, right anterior oblique. The majority of patients had paroxysmal AF (n=52), whereas a small number had persistent AF (n=8). None of the patients had long-standing persistent AF. They were at low risk for symptomatic thromboembolism (CHADS 2 , 0.6±0.7; CHA 2 DS 2 -VASc, 1.3±1.2). Patients had previously tried and failed flecainide (n=25), sotalol (n=19), propafenone (n=6), amiodarone (n=5), and dronedarone (n=14) before the ablation procedure.
Pre-Existing Cerebral MRI Lesions
The prevalence of subjects with PELs on preprocedure MRI was 60% (36/60), with a burden of 8 lesions per subject (interquartile range [IQR], 3-22; Figure 3 ). PEL had median volume of 166 mm 3 (IQR, 52-636). Lesions were predominantly in the white matter (99%). PELs were distributed in the frontal (56%), parietal (25%), insular (6.2%), subinsular (4.3%), temporal (3.2%), limbic (3.1%), and occipital (2.2%) lobes. Patients with PELs were older (P=0.03), were more likely to have hypertension (P=0.01), had larger left atrial diameter (P=0.02), and had higher CHADS 2 (P=0.03) and CHA 2 DS 2 -VASc scores (P=0.006; Table 1 ). Median number of lesions per patient by CHA 2 DS 2 -VASc score were: 0 (IQR, 0-2.5) for score 0; 3 (IQR, 0-6) for score 1; 2 (IQR, 1-17) for score 2; 23 (IQR, 0-37) for score 3; and 6.5 (IQR, 5-8) for score 4. By linear regression, there was a significant relationship between the number of chronic lesions and CHA 2 DS 2 -VASc score with an average of 4.9 (95% confidence interval [CI], 2.5-7.2) additional lesions for each point increase in the CHA 2 DS 2 -VASc score (R 2 =0.23; P<0.0001). Patients with PELs did not have any neurological differences with a mean preablation NIH Stroke Scale score of 0.1±0.4 compared with 0.3±0.8 in patients without PEL (P=0.23; Figure 4 ).
Procedural Parameters
Compliance with the ablation protocol was high ( Table 2 ). The average INR on the day of procedure was 2.4±0.5. The ACT just before initiation of ablation was 368±192 seconds and the mean procedural ACT was 405±116 seconds. All ablation catheters were introduced using the submerged technique for all procedures. Virtually all RF applications (99.8%) had either the distal or proximal electrode disabled on the circular MER catheter. Most subjects experienced a spontaneous or direct current cardioversion during the procedure (67%), with an average of 2.3±1.8 cardioversions per converted subject (55% of cardioversions were In the total study population, there were no significant changes in the MMSE or NIHSS scores from baseline to postprocedure or 1 month. There were also no significant differences in score changes between patients with baseline MRI showing chronic PEL and those with normal baseline MRI (No PEL). Edges of the box represent 25th and 75th percentile values and the whiskers represent minimum and maximum values that are within 1.5 times the interquartile range limits.
spontaneous; 45% were electrical). Total procedure time was 100±35 minutes with a LA time of 64±27 minutes. PV isolation was achieved in all subjects using only the circular MER catheter. At the 1-month follow-up visit, 53/60 subjects (88%) were in sinus rhythm (94% on antiarrhythmic drug therapy).
Incidence of ACE and Neurological Findings Postablation
The mean time elapsed after the ablation procedure until the postprocedural cerebral MRI was 28.2±16.3 hours. On the postablation MRI, 1 of 60 subjects (1.7%; 95% CI, 0.04-8.9) had any new ACE lesion seen. In this patient, there was only 1 new ACE lesion measuring 8×6 mm in the occipital lobe white matter ( Figure 5 ). This lesion was no longer visible on the 1-month follow-up MRI. This patient was a 58-year-old woman with a history of persistent AF. Her CHADS 2 score was 0 and CHA 2 DS 2 -VASc score was 1, and she had no PEL on preablation MRI. The patient had an INR of 2.0 on the day of ablation. During the procedure, the patient experienced an elevated procedural ACT of >900 seconds after the transseptal puncture for which intravenous protamine was administered.
No cardioversions were performed during the ablation. Gross neurological assessment postablation in this patient was unremarkable with a MMSE score of 29.0 and a NIH Stroke Scale score of 0.0 (baseline 30.0 and 0.0, respectively). At 1 month, the MMSE was 30.0 and the NIH Stroke Scale was still 0.0. In the total study population, there were no significant differences in the MMSE or NIH Stroke Scale scores between baseline, postprocedure, and at 1 month (Figure 4 ).
Adverse Events
No subjects experienced a symptomatic cerebral event. One subject experienced 2 right groin pseudoaneurysms that resolved upon localized thrombin injection 1 day after the procedure. No other serious adverse events were noted, including pericardial effusion or tamponade, atrial esophageal fistula, or death.
Discussion
Main Findings
This is the first multicenter study to demonstrate that through application of specific procedural changes, the rate of postablation ACE could be substantially reduced without affecting acute procedural efficacy or safety. Specifically, continuous oral anticoagulation coupled with aggressive procedural heparinization, submerged capture of the catheter into the introducer, and deactivation of the distal or proximal electrode to avoid their interaction effects reduced the incidence of ACE associated with a circular MER catheter to 1.7%. This is one of the lowest rates of ACE reported postablation with any ablation technology. None of the patients exhibited any gross neurological symptoms. This study also found that despite a low CHADS(-VASc) score of the study patients, 60% had pre-existing asymptomatic chronic cerebral lesions on their preablation MRI.
Mechanisms of ACE
Prior animal studies have demonstrated that direct arterial injection of either gaseous or microparticulate material similar to that generated by LA ablation can recreate the ACE lesions seen in patients post-AF ablation. 10 Three categories of embolic materials may be generated during LA ablation: (1) gaseous emboli produced from introduction of air in sheaths or during heating/boiling of blood; (2) particulate emboli ACT indicates activated clotting time; E1, distal electrode on the circular multielectrode radiofrequency (MER) catheter; E10, proximal electrode on the circular MER catheter; INR, international normalized ratio; and RF, radiofrequency.
*Spontaneous or direct current cardioversion to sinus rhythm. (char) because of denaturation of tissue; and (3) thromboemboli because of activation of the coagulation cascade. In animal studies with the circular MER catheter, it was found that the largest source of gaseous and solid emboli occurred when the distal and proximal electrodes of the catheter were in close proximity or overlapping. 10 This electrode overlap creates a bipolar short circuit resulting in excessive tissue and blood heating. By deactivating either the proximal or distal electrode in the current study, this important potential source of emboli was prevented.
The second largest source of gaseous emboli in the animal model was found to be introduction of air into the LA via the sheaths during catheter insertion and removal. By immersing the circular MER catheter in saline during introducer capture and by aspirating and flushing the sheath side arm, air embolism was also reduced in this study.
Finally, aggressive anticoagulation in this study mitigated any thromboembolic mechanism of ACE. Therapeutic oral VKA anticoagulation for ≥1 month before the ablation and continued uninterrupted periablation likely further reduced the chance of periprocedural thromboembolic complications. 6 Finally, use of a higher minimum procedural ACT of 350 seconds may also have further reduced embolic risk. 14 It is interesting that the only patient with an ACE lesion postablation also had a substantial dose of intraprocedural protamine. It is unclear if protamine contributed to the ACE lesion, especially because postprocedural protamine was used in 25/60 patients (42%) without ACE occurrence.
Incidence and Predictors of ACE
Prior studies have reported rates of ACE postablation ranging from 1.9% to 14.3% using traditional irrigated RF energy or cryoablation. 3, 6, 7, [15] [16] [17] [18] [19] [20] Two studies also suggested that the rate of ACE associated with MER circular catheters was significantly higher than the ACE rate associated with irrigated RF catheters. 7, 8 These 2 studies used an ACT cutoff of 300 seconds but used interrupted VKA with low-molecular-weight heparin bridging periablation. There was also no specific technique for loading/unloading the catheter and no avoidance of distal-proximal electrode interaction. Two subsequent studies then reported that through application of some procedural changes, post-MER ablation ACE rates could be reduced to the 5%-10% range. 15, 17 Wieczorek et al 15 used an uninterrupted VKA periablation strategy and careful underwater loading of the catheter with careful removal, with a mean ACT of 282. Their study was able to achieve ACE rates of <10%, suggesting the importance of VKA and sheath loading techniques. The only predictor of ongoing ACE was the interaction between the distal and proximal electrodes. Nardi et al 17 stressed the importance of keeping the distal and proximal electrodes apart without some of the other Wieczorek interventions, and their rate of ACE was even lower. In the current study, the ACE rate of 1.7% is one of the lowest ACE rates ever reported ( Figure 6 ), and in 1 patient who had a new ACE lesion, only 1 lesion was found measuring <10 mm. This would seem to stress the importance of employing all of the risk attenuation strategies, in particular avoiding the electrode Figure 6 . Summary of studies reporting on rates on asymptomatic cerebral emboli (ACE) immediately postablation (<24-48 h) using various technologies. The 1.7% incidence of ACE reported in this study is one of the lowest incidences of ACE reported for any technology. Error bars represent the 95% confidence interval of the point estimates for each study. The mean point estimates and upper and lower 95% confidence boundaries (CB) are listed below the graph. RF indicates radiofrequency energy. Dotted line represents data published with and without procedural techniques to reduce potential sources of microemboli. Dotted line represents data published with and without procedural techniques to reduce potential sources of microemboli.
interaction, during MER ablation. In fact, meticulousness during anticoagulation and sheath loading may help reduce ACE events regardless of ablation technology.
Prior studies also suggested that procedural ACT 3 and performing cardioversion 3 during the procedure were predictors of postablation ACE. ACT was likely found to be a predictor because the target of ACT in some prior studies was only ≈250 seconds. ACT levels of >300 seconds have been recommended by both studies 14 and guidelines 1 to better reduce thromboembolic risk, and in our study, ACT was always kept >350 seconds. In this study, two thirds of patients had a mean of 2.3 cardioversions per procedure. Yet, no ACE was detected in any of the converted patients. It would appear that cardioversion is not a major contributor to ACE in the setting of this trial.
Pre-existing Chronic MRI Lesions
A surprising finding of this study was the high prevalence (60%) and number of pre-existing MRI lesions seen in patients who were otherwise at low risk of chronic thromboembolism. This is higher than, but consistent with, rates of PEL reported in other studies, which have ranged from 12.3% to 58%. 5, 6, [15] [16] [17] 20 This shows that even in AF patients with low CHADS 2 risk scores, silent embolic lesions are still prevalent. This high burden of embolism and chronic scar formation caused by chronic AF has been shown to correlate with development of cognitive decline. [21] [22] [23] In contrast, the rate of chronic ACE lesions postablation is very low, ranging from 0% to 3.5%. Even in studies demonstrating high rates of immediate postprocedural ACE, many of these lesions become undetectable on MRI after 1 to 3 months. 5 This is not surprising because the bulk of emboli causing these lesions are likely gaseous and, therefore, cause only transient interruption of blood flow. 24 Furthermore, diffusion-weighted changes on MRI represent hyperacute cellular ischemia that does not necessarily progress to full cellular necrosis. 25 In the current study, the only ACE lesion detected postablation was no longer detected after 1 month. Thus, in the context of the substantial embolic risk posed by chronic AF, the contribution of catheter ablation to chronic cerebral change is quite small. If catheter ablation can reduce AF burden, it is possible that overall embolic load could also be reduced in the long term, resulting in a clear net clinical benefit. Further clinical investigation would be required to definitively answer this question.
Study Limitations
Although this study has reported an encouragingly low rate of ACE, it is only 1 study with a small to moderate number of patients. Second, this study was a single-arm cohort study without a comparative group. Thus, the incidence of ACE using alternative ablation technologies with similar procedural adjustments cannot be known from this data. Third, several procedural interventions were implemented simultaneously in this study; so it is impossible to determine the relative contributions of each intervention on the reduction in ACE rate. Based on prior animal data, the interaction between the distal and proximal electrodes was the single largest contributor to both gaseous and particulate emboli; so it could be hypothesized that this intervention was perhaps the most important measure implemented. Fourth, the neurological assessments in this study are intended for patients with suspected or symptomatic neurological impairment (MMSE and NIH Stroke Scale). Neither of these assessments can detect very subtle neurological changes, and it is possible that with highly detailed neuropsychological testing, subtle neurological changes may have been detected. Finally, neither the longterm efficacy of the MER ablation technology nor its potential to impact on chronic embolic load due to the AF disease process was assessed in this study.
Conclusions
Applying procedural changes to MER ablation significantly reduces the ACE incidence to 1.7%, which is one of the lowest reported rates of any technology. The changes do not impact acute safety or efficacy. In contrast, the prevalence of chronic preablation cerebral lesions is high despite low thromboembolic risk.
